New CMS Obesity Drug Coverage Could Cost States Billions

By Luke Zarzecki / November 27, 2024 at 3:00 PM

The National Association of Medicaid Directors (NAMD) is raising concerns over the cost implications of CMS’ unexpected proposal Tuesday (Nov. 26) to reinterpret federal law and allow coverage of GLP-1s to treat obesity under Medicare and Medicaid.


Not a subscriber? Sign up for 30 days free access to exclusive, detailed reporting on drug pricing reforms, Medicaid policy, FDA news and much more.